Elizabeth Miller
Elizabeth Miller
Verified email at
Cited by
Cited by
Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association
B Taylor, E Miller, CP Farrington, MC Petropoulos, I Favot-Mayaud, J Li, ...
The Lancet 353 (9169), 2026-2029, 1999
Impact of anti-vaccine movements on pertussis control: the untold story
EJ Gangarosa, AM Galazka, CR Wolfe, LM Phillips, E Miller, RT Chen, ...
The Lancet 351 (9099), 356-361, 1998
Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study
E Miller, K Hoschler, P Hardelid, E Stanford, N Andrews, M Zambon
The Lancet 375 (9720), 1100-1108, 2010
Effectiveness of maternal pertussis vaccination in England: an observational study
G Amirthalingam, N Andrews, H Campbell, S Ribeiro, E Kara, K Donegan, ...
The Lancet 384 (9953), 1521-1528, 2014
Consequences of confirmed maternal rubella at successive stages of pregnancy
E Miller, JE Cradock-Watson, TM Pollock
The Lancet 320 (8302), 781-784, 1982
Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases
G Enders, I Bolley, E Miller, J Cradock-Watson, M Ridehalgh
The Lancet 343 (8912), 1548-1551, 1994
Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study
E Miller, NJ Andrews, PA Waight, MPE Slack, RC George
The Lancet infectious diseases 11 (10), 760-768, 2011
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
CL Trotter, NJ Andrews, EB Kaczmarski, E Miller, ME Ramsay
The Lancet 364 (9431), 365-367, 2004
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study
PA Waight, NJ Andrews, SN Ladhani, CL Sheppard, MPE Slack, E Miller
The Lancet infectious diseases 15 (5), 535-543, 2015
Population‐based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40
WA Knowles, P Pipkin, N Andrews, A Vyse, P Minor, DWG Brown, E Miller
Journal of medical virology 71 (1), 115-123, 2003
Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story
E Miller, D Salisbury, M Ramsay
Vaccine 20, S58-S67, 2001
Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study
NJ Andrews, PA Waight, P Burbidge, E Pearce, L Roalfe, M Zancolli, ...
The Lancet infectious diseases 14 (9), 839-846, 2014
Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis
ME Ramsay, NJ Andrews, CL Trotter, EB Kaczmarski, E Miller
Bmj 326 (7385), 365-366, 2003
Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study
SN Ladhani, S Collins, A Djennad, CL Sheppard, R Borrow, NK Fry, ...
The Lancet Infectious Diseases 18 (4), 441-451, 2018
Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study
B Taylor, E Miller, R Lingam, N Andrews, A Simmons, J Stowe
Bmj 324 (7334), 393-396, 2002
Patient risk factors for adverse drug events in hospitalized patients
DW Bates, EB Miller, DJ Cullen, L Burdick, L Williams, N Laird, ...
Archives of internal medicine 159 (21), 2553-2560, 1999
Meningococcal surrogates of protection—serum bactericidal antibody activity
R Borrow, P Balmer, E Miller
Vaccine 23 (17-18), 2222-2227, 2005
Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England
ME Ramsay, N Andrews, EB Kaczmarski, E Miller
The lancet 357 (9251), 195-196, 2001
A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines
P Farrington, M Rush, E Miller, S Pugh, A Colville, A Flower, J Nash, ...
The Lancet 345 (8949), 567-569, 1995
Once-and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes
LS Phillips, G Grunberger, E Miller, R Patwardhan, EB Rappaport, ...
Diabetes care 24 (2), 308-315, 2001
The system can't perform the operation now. Try again later.
Articles 1–20